Pharmacology Research Unit
The Pharmacology Research Unit is an academically based experienced unit providing expertise and capacity for running experimental pain pharmacological studies and offering in addition a range of trial-related services. The Pharmacology Research Unit is a combination of a Clinical Research Organization (CRO) and a Clinical Trial Unit (CTU) and professionally offers all tasks related to drug trials.
Mission
The mission of the Pharmacology Research Unit is to evaluate and reveal pharmacological mechanisms and effects in models of experimental pain. This is based on qualified selection of reproducible and validated model, assessment and evaluation methods, resulting in high quality drug trials. The first sponsor initiated study was performed 10 years ago and therefore the team has great experience in performing such studies. With fully equipped laboratories, the unit can provide safe research with access to healthy volunteers and a variety of patient groups.
Visceral pain research
The Pharmacology Research Unit is placed in Department of Gastroenterology at Aalborg Hospital in Denmark. Methods for visceral pain stimulation has been invented and patented in Mech-Sense. Hereby the unique chance for visceral pain research exists. Visceral pain is different from somatic pain and pathophysiology and the mechanisms behind visceral pain conditions remain poorly understood. This lack of knowledge makes treatment of visceral pain challenging and often suboptimal. Therefore, evaluating analgesic effect in experimental visceral pain models is essential and could bridge the gap in knowledge between animal studies and clinical condition in patients suffering from visceral pain.
Pharmacological mechanisms can be revealed in the phase of drug discovery (Phase I) where the experimental pharmacology research unit expects to improve the speed of clinical research, by revealing important drug mechanisms in an earlier state and hereby lower the total cost of final clinical research. The main focus in Phase I clinical trials of analgesic effects has traditionally been the assessment of safety and tolerability. However, in recent years there has been increasing interest in the application of biomarkers and surrogate end points in healthy volunteer studies to provide pivotal information on efficacy, dose-response and time-effects of drugs. Finally, experimental pharmacological studies are important tools when clinical behaviour needs explanation (Phase IV-V).
Quickly and Cost-effectively drug development
The pharmaceutical industry itself has a growing pressure to develop medicines more quickly and cost-effectively with earlier read-outs on putative efficacy or potential development obstacles obtained. Our cutting edge pharmacodynamic models can provide this for you.
|
